Водородна Терапия при Лечение на ХипертонияНаучно Изследване
оригинално заглавие (букв. прев.): Ефектът от вдишване на ниска доза водородо-кислородна смес при възрастни на средна възраст/възрастни с хипертония: Рандомизирано, плацебо-контролирано проучване
1Taishan Institute for Hydrogen Biomedicine, the Second Affiliated Hospital of Shandong First Medical University and Shandong Academy of Medical Sciences, Tai’an, Shandong, China
2College of Nursing, Shandong First Medical University and Shandong Academy of Medical Sciences, Tai’an, Shandong, China
Публикувано на: 07/10/2022
Да се проучи ефектът от инхалация на водородо-кислород (H2-O2) в ниски дози при възрастни на средна възраст/възрастни с хипертония.
Проучването включва 60 участници с хипертония на възраст 50-70 години, които са разделени на случаен принцип в група “Air” (инхалации с плацебо въздух) и група “H2-O2” [инхалации с кислородо-водородна смес H2-O2 (66% H2 и 33% O2)].
Участниците и в двете групи са лекувани по 4 часа на ден в продължение на 2 седмици. Преди и след интервенцията са проследени кръвното налягане на четирите крайника, както и 24-часовото амбулаторно кръвно налягане и са определени нивата на плазмените хормони, свързани с хипертонията.
Общо 56 пациенти завършват проучването (27 в групата “Air” и 29 в групата “H2-O2“). Систоличното кръвно налягане (SBP) на дясната и лявата ръка е понижено значително при пациентите, на които са приложени инхалации с водородо-кислород (H2-O2) в сравнение с нивата в началото на проучването – съответно от 151,9 ± 12,7 mmHg до 147,1 ± 12,0 mmHg и от 150,7 ± 13,3 mmHg до 145,7 ± 13,0 mmHg (всички с p<0.05).
Същевременно интервенцията с H2-O2 значително намалява нощното амбулаторно диастолно (диастолично) кръвно налягане с 2,7 ± 6,5 mmHg (p <0,05). В групата на пациентите, на които е приложен плацебо, всички стойности на кръвното налягане не се повлияват (всички са със стойност p>0,05).
При стратифициране/подреждане по възраст (50-59г. спрямо 60-70г.), в групата на участниците на възраст между 60г. и 70г., на които са приложени инхалации с водородо-кислород (H2-O2), показват по-голямо намаление на SBP на дясната ръка в сравнение с тези в група на по-младите (p<0,05). В допълнение, нивата на ангиотензин II, алдостерон и кортизол, както и съотношението алдостерон-ренин в плазмата, са значително понижени в “H2-O2” групата спрямо началните нива (p < 0,05). При участниците от група “Air” преди и след интервенцията не са наблюдавани значителни разлики.
Заключение от Проучването
Инхалирането с водородо-кислород (смес от H2 и O2) в ниски дози оказва благоприятно въздействие върху кръвното налягане. Намалява плазмените нива на хормоните, свързани с хипертонията и стреса при възрастни хора на средна възраст и възрастни с хипертония.
ORIGINAL RESEARCH articleFront. Pharmacol., 07 October 2022
Sec. Cardiovascular and Smooth Muscle Pharmacology
This article is part of the Research Topic
Gaseous Signalling Molecules: Cardiovascular Significance and Molecular Mechanisms
Hypertension is a long-term medical condition that increases the risk of serious problems including heart attacks and strokes. Globally, hypertension is estimated to affect 1.4 billion people (Egan et al., 2019) and its prevalence increases with age. Among Westerners aged over 40 years, systolic blood pressure (SBP) increases by about 7 mmHg per decade (Wolf-Maier et al., 2003), and over 65% of midlife/older (aged ≥50 years) adults in the United States present with above-normal SBP (Virani et al., 2020; Craighead et al., 2021).
Lifestyle adjustments, including physical exercise, dietary changes, quitting smoking and restricting alcohol, are generally effective in lowering blood pressure. When lifestyle changes alone cannot achieve the desired result, specific medications are needed. Current drugs for hypertension include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta blockers, and renin inhibitors. The majority of patients with hypertension require a combination of at least two blood pressure lowering medications to achieve recommended goals (Bruyn et al., 2022). However, recent data have shown that less than 15.3% of individuals with hypertension in China meet the recommended target of blood pressure, and many require an increased medication dosage or additional medications to achieve blood pressure control (Bundy and He, 2016; Wang et al., 2018). In the low- and middle-income countries, only 30% of patients with hypertension had received treatment and only 10.3% had controlled hypertension (Geldsetzer et al., 2019). Thus, it is necessary to develop safe and effective adjuvant therapies to lower blood pressure.
Hydrogen (h3) has been regarded as a novel gaseous signaling molecule with cardiovascular therapeutic potential. A previous study indicated that 1 h of daily exposure to a low dose h3 (1.3%, v/v) for 4 weeks exerted an antihypertensive effect in rats with hypertension induced by 5/6 nephrectomy (Sugai et al., 2020). Meanwhile, h3 therapy showed benefits in alleviating hypertension-related organ damage. For instance, inhalation of 2% h3 gas (Matsuoka et al., 2019) or intraperitoneal injection of h3-rich saline (Yu and Zheng, 2012) improved left ventricular hypertrophy in different hypertensive rats, and consumption of h3-rich water alleviated renal injury in spontaneous hypertensive rats (Xin et al., 2014). Another clinical study demonstrated that h3-enriched dialysate improved blood pressure control in chronic dialysis patients (Nakayama et al., 2018). However, the effect of h3 in lowering hypertensive blood pressure remains controversial.
A high dose of hydrogen–oxygen (h3-O2) mixture (66% h3/33% O2) supplied via inhalation at a flow rate of approximately 6 L/min or 3 L/min via nasal cannula has been demonstrated to relieve dyspnea and other respiratory symptoms in patients with coronavirus disease 2019 (Guan et al., 2020) and to improve the quality of life in patients with cancer (Chen et al., 2019). However, the large size and expensive cost make it inconvenient for domiciliary medical care in daily life. As a simple and low-cost treatment, the clinical effects of a low-dose 66% h3/33% O2 inhalation (flow rate 30–60 ml/min) have gained increasing interest in recent years. Therefore, we performed a randomized, placebo-controlled trial in hypertensive patients aged 50–70 with baseline right arm SBP ≥120 mmHg to test the efficacy of a low-dose h3-O2 mixture inhalation in patients with hypertension.
Materials and methods
This study comprised a 2-week randomized, placebo-controlled, single-center, single-blind, parallel-design clinical trial that was conducted from November 2021 to January 2022. After obtaining informed consent, all participants were randomly allocated to a control Air group or h3-O2 group. The trial was approved by The Ethics Committee of Shandong First Medical University and Shandong Academy of Medical Sciences (R202107080165) and was registered at China Clinical Trial Registry (CHiCTR2100049865). All procedures were conducted in accordance with the principles of the Declaration of Helsinki.
Potential participants were recruited from community residents aged 50–70 years diagnosed with hypertension and with established health records at Fenghuang Community Health Service Station in Tai’an, Shandong, China. Participants with right arm SBP of ≥120 mmHg by four-limb blood pressure measurement were enrolled. Individuals taking ≥3 kinds of antihypertensive drugs or with a history of major diseases and surgery, such as heart failure, malignant tumor, or organ resection, were excluded. The discontinuation criteria were withdrawal of consent, lack of compliance, or other medical reasons that required the intervention to be terminated. Participants were randomized by computer-based stratification (1:1), which was determined by age (50–59 years, 60–70 years) and gender. Allocation was concealed in opaque envelopes until the beginning of the intervention.
Sample size calculation
An appropriate sample size (n = 52) was calculated using the power analysis (effect size d 0.8, α err prob 0.05, power (1-β err prob) 0.8, allocation ratio N2/N1 1) for the primary treatment outcome (G-power 184.108.40.206). To accommodate for a 15% attrition rate, we planned to recruit a total of 60 patients.
All participants were asked to maintain their usual diet, lifestyle, and medication. Participants in the h3-O2 group inhaled a mixture of 66% h3 and 33% O2 for a total of 4 h every day at their convenience for two consecutive weeks. The gas was generated from a h3-O2 Generator (Small H Portable Hydrogen-Oxygen Generator D-HO-001, Jinkai Instrument Co., Ltd., Dalian, China). The flow rate was approximately 30–60 ml/min, and the h3 concentration inhaled by the participants during breathing was about 0.2%–0.4%. The Air group inhaled normal air from a machine with the same appearance. Participants were asked to record the intervention time every day.
The primary outcome in this study was the right arm SBP, and the secondary outcomes were other blood pressure variables and related blood indexes.
The values of four-limb blood pressure were automatically and simultaneously measured in an air-conditioned room at the temperature of 22–26°C via an arteriosclerosis detector (BP-203RPE Ⅲ, Omron, Japan) with participants in the supine position after resting for more than 5 min. A trained technician placed the pressure cuffs on both arms and both ankles for two consecutive measurements at 1-min interval, and the average value of the two results was recorded.
Assessment of the 24-h ambulatory blood pressure (ABP) monitoring was performed by an ABP detector (ABP-06, Bosheng, China). Participants were instructed to perform their habitual daily activities. The cuff was of proper size and worn on the right upper limb. ABP measurements were recorded every 30 min during the day (7:00 a.m.–10:00 p.m.) and every 60 min at night (10:00 p.m.–7:00 a.m.). The criteria for valid ABP recordings included at least 70% valid readings and at least one valid reading per hour for 21 h.
Blood samples after overnight fasting were collected into tubes containing EDTA at the beginning and end of the study. Plasma was isolated immediately by centrifugation at 3,000 × g for 15 min at 4°C and stored at −80°C until further analysis. Plasma creatinine, uric acid, total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, glucose, homocysteine, high sensitivity C-reactive protein (hsCRP), and lipoprotein associated phospholipase A2 (LP-PLA2) levels were determined using an automated chemistry analyzer (AU5821, Beckman Coulter, California, United States). Plasma cortisol, angiotensin Ⅱ, aldosterone, and renin levels were analyzed using an automatic chemiluminescence immunoanalyzer (A2000 PLUS, Antu Biological Engineering Co., Ltd, Zhengzhou, China). Superoxide dismutase (SOD) activity was measured with an assay kit (Nanjing Jiancheng, Nanjing, China).
Data were tested for normal distribution by the Shapiro–Wilk test. Those data conforming to the normal distribution are expressed by mean ± standard deviation (mean ± SD), and the unpaired t-test and paired t-test were used to detect inter and intra group differences, respectively. Data not conforming to the normal distribution are represented by median (Quantile 1 and Quantile 3); comparisons between groups were made using Mann–Whitney U-test (unpaired) and Wilcoxon signed rank test (paired). Differences were considered significant when p < 0.05. All analyses were performed using SPSS 26.0 software (IBM, Armonk, NY).
A total of 111 participants consented to be in the study. Fifty-one participants were either excluded based on the inclusion and exclusion criteria or withdrew before study randomization. Sixty participants were finally recruited and equally randomized to the Air group (n = 30) or h3-O2 group (n = 30). During the follow-up, three participants in the Air group and one participant in the h3-O2 group withdrew from the study. Finally, 27 subjects in the Air group and 29 subjects in the h3-O2 group completed the 2-week follow-up study (Figure 1). No side effects were reported in either group. Characteristics of the participants who completed the study were well matched between the two groups, with no significant differences (p > 0.05, Table 1).FIGURE 1
FIGURE 1. Trial flowchart.TABLE 1
TABLE 1. Baseline characteristics of study subjects.
The primary outcome of right arm SBP significantly decreased from 151.9 ± 12.7 mmHg at baseline to 147.1 ± 12.0 mmHg after 2 weeks of h3-O2 intervention (p < 0.05) but was unchanged in the Air group (p > 0.05) (Figure 2A and Supplementary Table S1). A similar finding was noted in the left arm SBP, which showed the SBP was significantly decreased from 150.7 ± 13.3 mmHg at baseline to 145.7 ± 13.0 mmHg in the h3-O2 group (p < 0.05, Figure 2C and Supplementary Table S1). The diastolic blood pressures (DBP) in both arms and all the blood pressures in both ankles showed no significant treatment effect in either group (all p > 0.05, Figures 2B, D–H and Supplementary Table S1).FIGURE 2
FIGURE 2. Four-limb blood pressure at baseline and after 2 weeks of intervention. SBP, systolic blood pressure; DBP, diastolic blood pressure. Data are represented as the mean ± SD; *p < 0.05 by paired t-test.
The 24-h SBP, 24-h DBP, daytime SBP, daytime DBP, and nighttime SBP did not change significantly across the intervention in the two groups (all p > 0.05, Table 2). A beneficial, but not significant trend, was observed for nighttime SBP in the h3-O2 group (p > 0.05, Table 2). Nighttime DBP decreased from 74.3 ± 9.9 mmHg at baseline to 71.6 ± 9.3 mmHg after 2 weeks of h3-O2 intervention (p < 0.05, Table 2) but was unchanged in the Air group (p > 0.05, Table 2).TABLE 2
TABLE 2. Ambulatory blood pressure.
Participants in the Air and h3-O2 groups were then stratified by age (aged 50–59 years versus aged 60–70 years), gender (male versus female), and body mass index (BMI) (BMI < 26 versus BMI ≥26). The older h3-O2 group showed a larger reduction in right arm SBP compared with that of the younger group (p < 0.05, Figure 3A). However, there were no significant effects according to gender and BMI (p > 0.05, Figures 3B,C). The reduction of right arm DBP in the older h3-O2 group was also significantly different from that of the younger group (p < 0.05, Supplementary Table S2). No obvious age-specific effects were observed in left arm, right ankle, and left ankle blood pressures (all p > 0.05, Supplementary Table S2) or ABPs (Supplementary Table S3).FIGURE 3
FIGURE 3. Changes in right arm SBP from baseline stratified by age(A), gender (B), and BMI (C). BMI, Body mass index. Data are represented as the mean ± SD; *p < 0.05 by unpaired t-test.
The renin–angiotensin–aldosterone system (RAAS) is a major hormonal cascade in the control of blood pressure. As shown in Table 3, after 2 weeks, plasma levels of cortisol, angiotensin Ⅱ, and aldosterone, as well as the aldosterone-to-renin ratio in the h3-O2 group were significantly lower compared with those at baseline (all p < 0.05), but there was no significant change in the Air group (all p > 0.05). The levels of renin showed no statistically significant changes after the either intervention (all p > 0.05). The h3-O2 group showed no significant changes in the plasma lipid levels of total cholesterol, triglyceride, HDL cholesterol, or LDL cholesterol; renal function indicators of urea, creatinine, or uric acid; oxidative marker of SOD activity; inflammatory indicators of hsCRP and LP-PLA2; plasma glucose; or homocysteine level (all p > 0.05, Table 3). We further stratified the changes in hormones related to hypertension in plasma by age (aged 50–59 years versus aged 60–70 years). However, these changes did not reach significant differences in each group (all p > 0.05, Supplementary Table S4).TABLE 3
TABLE 3. Plasma biochemical parameters at baseline and after the 2-week intervention.
The current study conducted a randomized, controlled, parallel-design trial to evaluate the effect of a low-dose 66% h3/33% O2 mixture on the blood pressure of midlife/older adults with hypertension. We found that the 2-week h3-O2 intervention reduced right arm SBP, and the reduction in participants aged 60–70 years was significantly larger compared with that of those aged 50–59. In addition, the h3-O2 intervention improved the plasma hormone levels of cortisol, angiotensin Ⅱ, aldosterone, and reduced the aldosterone-to-renin ratio compared with the baseline levels.
h3 has been traditionally regarded as a biologically inert gas. However, in 2007, scholars discovered that h3 can exert antioxidant properties and prevent ischemia-reperfusion injury in a rat model (Ohsawa et al., 2007). Since then, a large number of studies have explored the therapeutic and preventive effects of h3 in different diseases, including metabolic diseases, neurological diseases, cancer, and many aging-related diseases (Liu et al., 2020; Liu et al., 2021; Fu et al., 2022).
The primary outcome of the right arm SBP was significantly reduced with approximately 4.8 mmHg after 2 weeks of h3-O2 intervention. However, the reduction in casual DBP did not reach significant difference. This may be attributable to aging is not associated with increases in DBP as reported in a previous study (Lakatta et al., 2003). For ambulatory blood pressure, h3-O2 intervention led to a decreasing trend in nighttime SBP and a significant decrease in nighttime DBP in comparison with baseline, while no changes were observed in the Air group. Certain reports have noted that sleep problems or disorders, such as sleep loss, sleep-disordered breathing, and sleep apnoea, are associated with hypertension (Nieto et al., 2000; Calhoun and Harding, 2010). A clinical study has suggested that the sleep quality of healthy people can be improved after a 4-week period of h3-water drinking (Tanaka et al., 2018). The influences of h3-O2 intervention on sleep and the potential effects on hypertensive are needed for further investigation.
There are several possible mechanisms by which h3 may lower blood pressure. The RAAS is a group of related hormones that act together to regulate blood pressure (Mentz et al., 2013). In RAAS, renin reacts with angiotensin converting enzyme to form angiotensin II, which plays a strong biological role in raising blood pressure by constricting blood vessels. It also triggers the secretion of aldosterone, which can enhance the reabsorption of sodium and water into the bloodstream from the kidney, increase the volume of fluid in the body, and also increase blood pressure (Atlas, 2007; Kobori et al., 2007). Our results show the significant effect of h3 inhalation on plasma angiotensin Ⅱ and aldosterone as well as the aldosterone-to-renin ratio, which may partly attribute to the blood pressure lowering effect. The detailed mechanism of h3 on the RAAS requires further investigation.
A higher level of the stress hormone cortisol is also linked to an increased risk of hypertension and cardiovascular events (Whitworth et al., 2000). Our research also showed that a 2-week low-dose of 66% h3/33% O2 inhalation could reduce the plasma cortisol level in patients with hypertension. It is well known that cortisol is significantly increased by psychological stressors, especially in chronic stressful events. Our result indicates that the sympathetic function of the autonomic nervous system may be suppressed by h3 inhalation. This calls for future studies to elucidate the mechanism of h3 in reducing stress.
Oxidative stress seems to be a common feature of hypertensive states. Several clinical trials have indicated that antioxidant therapy is important for the management of hypertension (Ahmad et al., 2017). h3 has been reported to selectively reduce reactive oxygen species (ROS) such as hydroxyl radicals and peroxynitrite anions to exert therapeutic antioxidant activity (Ohsawa et al., 2007). Previous studies demonstrated that h3 treatment reduced oxidative stress in different animal models with elevated blood pressure (Yu and Zheng, 2012; Guan et al., 2019). SOD is an important antioxidant enzyme that can modulate ROS levels. Studies have shown that the activity of SOD was significantly lower in the whole blood in hypertensive patients as compared to those in the normotensive subjects (Ahmad et al., 2013). However, in the present study, the oxidative marker of SOD activity did not change significantly. Many studies have demonstrated the importance of ROS production by NADPH oxidases activated by angiotensin II in hypertension (Garrido and Griendling, 2009). Thus, h3 may exert the free radical scavenging effects partially through angiotensin II signaling. The effect of h3 inhalation on oxidative stress in hypertension patient also needs further study.
Inflammatory processes play an important role in the pathophysiology of hypertension. Cytokines, toll-like receptors, and specific immune cell types are novel targets for antihypertensive therapy (De Miguel et al., 2015). A clinical trial has indicated that adding h3 to hemodialysis solutions can ameliorate inflammatory reactions and improve blood pressure (Nakayama et al., 2010). Wang et al. used h3-rich saline for the treatment of pulmonary hypertension in a rat model and reported decreased amounts of pro-inflammatory cytokines in serum (Wang et al., 2011). These results provided evidence that h3 improves the inflammatory processes of hypertension. However, in this study the inflammation-related biomarker hsCRP was not significantly improved, and more indicators should be tested further.
It is worth noting that the plasma levels of LDL cholesterol, creatinine, and LP-PLA2 increased in the Air group after 2 weeks, however the h3-O2 intervention showed the potentially protective effects. h3 has been reported to exert a wide range of therapeutic effects. Nonetheless, the underlying mechanism of its role remains ambiguous. To explore the specific molecular mechanism responsible for these effects of h3 will promote its clinical applications. Notably, it seems that the older the age, the more obvious the effect of the blood pressure intervention. Vascular wall thickening, elastic fiber reduction or even fracture calcification, increased peripheral resistance, decreased vascular compliance, and other factors will lead to an increase in blood pressure with age (Borzecki et al., 2006; Mceniery et al., 2007). h3, as a simple biomedical gas, has also been proved to be a possible antiaging agent. A recent clinical trial revealed that a 6-month intake of h3-rich water positively affected several molecular and phenotypic biomarkers of aging in older adults (Zanini et al., 2021). Our previous study in a D-galactose-induced aging mice model demonstrated that h3 administered by different routes can prevent oxidative stress and exert antiaging effects (Liu et al., 2021a). Thus, h3 may be used for the prevention and treatment of various aging-related diseases.
Clinically, h3 can be administered to humans via different routes, such as h3 gas inhalation (Tao et al., 2022), h3-rich water drinking (Si et al., 2021), and direct incorporation of h3 through diffusion (such as local hydrogen water packing (Yang et al., 2019) or h3-water bathing (Zhu et al., 2018)). The dose–response relation of h3 is worthy of deep research. A previous study compared the protective effect of h3 following different routes of administration in D-galactose-induced aging mice and found that although oral h3-water resulted in limited h3-intaking compared with that of h3 inhalation, it resulted in the same efficacy in most oxidative stress-related indicators (Liu et al., 2021). In another animal model of ischemia–reperfusion injury, lower concentrations of h3 (0.5%–2%) provided better effects than those of 4% h3 inhalation (Hayashida et al., 2008). In the present study, 30–60 ml/min of 66% h3/33% O2 inhalation showed benefits in patients with hypertension. Additional research is required to identify the optimal method and dosage of h3 application for different diseases.
There are several limitations of our study. First, the daily intervention times were set by the participants; thus, we were unable to identify the optimal timing. Second, although the low-dose 66% h3/33% O2 mixture played a contributing role in reducing blood pressure, the optimal concentration for h3 inhalation in improving hypertension deserves further investigation. Third, the sample size of the study was relatively small, and we lacked delayed follow-up data (e.g., a 6-month follow-up survey). The strengths of our study include its randomized, blinded, placebo-controlled design, the use of four-limb and 24-h blood pressure measurements, and the high compliance rate.
In conclusion, inhalation of a low-dose 66% h3/33% O2 mixture exerts a favorable effect on improving blood pressure in midlife/older adults with hypertension. According to the age stratification, the intervention was more effective among patients aged 60–70 years than among those aged 50–59 years. Possible mechanisms of h3 in regulating blood pressure may be the inhibitory effect on the RAAS and stress. The current findings will provide important insight into the application of h3 inhalation as an effective and acceptable method for patients with hypertension.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
The studies involving human participants were reviewed and approved by The Ethics Committee of Shandong First Medical University and Shandong Academy of Medical Sciences (R202107080165). The patients/participants provided their written informed consent to participate in this study.
SQ, BL, XJ, and YX conceived and designed the experiments. XJ, BL, and YaX conducted sample recruitment and quality control. XJ, BL, YX, XiJ, and JZ performed the experiments. XJ and BL undertook data processing and statistical analysis. BL, XJ, YX, and SQ interpreted the results. BL, XJ, and SQ wrote, reviewed, and edited the manuscript. All authors contributed to the article and approved the submitted version.
This work was supported by the National Natural Science Foundation of China (81770855) and Academic promotion programme of Shandong First Medical University (2019QL010).
We acknowledge Jinkai Instrument Co., Ltd. (Dalian, China) for their products, and Dalian Institute of Chemical Physics, Chinese Academy of Sciences for the technical support of the products.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.1025487/full#supplementary-material
Ahmad, A., Singhal, U., Hossain, M. M., Islam, N., and Rizvi, I. (2013). The role of the endogenous antioxidant enzymes and malondialdehyde in essential hypertension. J. Clin. Diagn. Res. 7, 987–990. doi:10.7860/JCDR/2013/5829.3091
Ahmad, K. A., Yuan Yuan, D., Nawaz, W., Ze, H., Zhuo, C. X., Talal, B., et al. (2017). Antioxidant therapy for management of oxidative stress induced hypertension. Free Radic. Res. 51, 428–438. doi:10.1080/10715762.2017.1322205
Atlas, S. A. (2007). The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition. J. Manag. Care Pharm. 13, 9–20. doi:10.18553/jmcp.2007.13.s8-b.9
Borzecki, A. M., Glickman, M. E., Kader, B., and Berlowitz, D. R. (2006). The effect of age on hypertension control and management. Am. J. Hypertens. 19, 520–527. doi:10.1016/j.amjhyper.2005.10.022
Bruyn, E., Nguyen, L., Schutte, A. E., Murphy, A., Perel, P., and Webster, R. (2022). Implementing single-pill combination therapy for hypertension: A scoping review of key health system requirements in 30 low-and middle-income countries. Glob. Heart 17, 6. doi:10.5334/gh.1087
Bundy, J. D., and He, J. (2016). Hypertension and related cardiovascular disease burden in China. Ann. Glob. Health 82, 227–233. doi:10.1016/j.aogh.2016.02.002
Calhoun, D. A., and Harding, S. M. (2010). Sleep and hypertension. Chest 138, 434–443. doi:10.1378/chest.09-2954
Chen, J.-B., Kong, X.-F., Lv, Y.-Y., Qin, S.-C., Sun, X.-J., Mu, F., et al. (2019). Real world survey” of hydrogen-controlled cancer: A follow-up report of 82 advanced cancer patients. Med. Gas. Res. 9, 115–121. doi:10.4103/2045-9912.266985
Craighead, D. H., Heinbockel, T. C., Freeberg, K. A., Rossman, M. J., Jackman, R. A., Jankowski, L. R., et al. (2021). Time‐efficient inspiratory Muscle strength training lowers blood pressure and improves endothelial function, NO bioavailability, and oxidative stress in midlife/older adults with above‐normal blood pressure. J. Am. Heart Assoc. 10, e020980. doi:10.1161/JAHA.121.020980
De Miguel, C., Rudemiller, N. P., Abais, J. M., and Mattson, D. L. (2015). Inflammation and hypertension: New understandings and potential therapeutic targets. Curr. Hypertens. Rep. 17, 507–510. doi:10.1007/s11906-014-0507-z
Egan, B. M., Kjeldsen, S. E., Grassi, G., Esler, M., and Mancia, G. (2019). The global burden of hypertension exceeds 1.4 billion people: Should a systolic blood pressure target below 130 become the universal standard? J. Hypertens. 37, 1148–1153. doi:10.1097/HJH.0000000000002021
Fu, Z., Zhang, J., and Zhang, Y. (2022). Role of molecular hydrogen in ageing and ageing-related diseases. Oxid. Med. Cell. Longev. 2022, 2249749. doi:10.1155/2022/2249749
Garrido, A. M., and Griendling, K. K. (2009). NADPH oxidases and angiotensin II receptor signaling. Mol. Cell. Endocrinol. 302, 148–158. doi:10.1016/j.mce.2008.11.003
Geldsetzer, P., Manne-Goehler, J., Marcus, M.-E., Ebert, C., Zhumadilov, Z., Wesseh, C. S., et al. (2019). The state of hypertension care in 44 low-income and middle-income countries: A cross-sectional study of nationally representative individual-level data from 1· 1 million adults. Lancet 394, 652–662. doi:10.1016/S0140-6736(19)30955-9
Guan, P., Lin, X. M., Yang, S. C., Guo, Y. J., Li, W. Y., Zhao, Y. S., et al. (2019). Hydrogen gas reduces chronic intermittent hypoxia‐induced hypertension by inhibiting sympathetic nerve activity and increasing vasodilator responses via the antioxidation. J. Cell. Biochem. 120, 3998–4008. doi:10.1002/jcb.27684
Guan, W.-J., Wei, C.-H., Chen, A.-L., Sun, X.-C., Guo, G.-Y., Zou, X., et al. (2020). Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial. J. Thorac. Dis. 12, 3448–3452. doi:10.21037/jtd-2020-057
Hayashida, K., Sano, M., Ohsawa, I., Shinmura, K., Tamaki, K., Kimura, K., et al. (2008). Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia–reperfusion injury. Biochem. Biophys. Res. Commun. 373, 30–35. doi:10.1016/j.bbrc.2008.05.165
Kobori, H., Nangaku, M., Navar, L. G., and Nishiyama, A. (2007). The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59, 251–287. doi:10.1124/pr.59.3.3
Lakatta, E. G., Levy, D., Liu, B., Xie, Y., Chen, J., Xue, J., et al. (2003). Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises: Part I: Aging arteries: A “set up” for vascular disease. Circulation 107Protective effect of molecular hydrogen following different routes of administration on D-galactose-induced aging mice. J. Inflamm. Res. 14, 1395541–1395550. doi:10.2147/jir.s332286
Liu, B., Xue, J., Zhang, M., Wang, M., Ma, T., Zhao, M., et al. (2020). Hydrogen inhalation alleviates nonalcoholic fatty liver disease in metabolic syndrome rats. Mol. Med. Rep. 22, 2860–2868. doi:10.3892/mmr.2020.11364
Liu, B., Zhao, M., Xue, J., Gu, Q., Zhang, X., and Qin, S. (2021). Hydrogen influences HDL-associated enzymes and reduces oxidized phospholipids levels in rats fed with a high-fat diet. Life Sci. 267, 118945. doi:10.1016/j.lfs.2020.118945
Matsuoka, H., Miyata, S., Okumura, N., Watanabe, T., Hashimoto, K., Nagahara, M., et al. (2019). Hydrogen gas improves left ventricular hypertrophy in Dahl rat of salt-sensitive hypertension. Clin. Exp. Hypertens. 41, 307–311. doi:10.1080/10641963.2018.1481419
Mceniery, C. M., Wilkinson, I. B., and Avolio, A. P. (2007). Age, hypertension and arterial function. Clin. Exp. Pharmacol. Physiol. 34, 665–671. doi:10.1111/j.1440-1681.2007.04657.x
Mentz, R. J., Bakris, G. L., Waeber, B., Mcmurray, J. J., Gheorghiade, M., Ruilope, L. M., et al. (2013). The past, present and future of renin–angiotensin aldosterone system inhibition. Int. J. Cardiol. 167, 1677–1687. doi:10.1016/j.ijcard.2012.10.007
Nakayama, M., Itami, N., Suzuki, H., Hamada, H., Yamamoto, R., Tsunoda, K., et al. (2018). Novel haemodialysis (hd) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study. Sci. Rep. 8, 254. doi:10.1038/s41598-017-18537-x
Nakayama, M., Nakano, H., Hamada, H., Itami, N., Nakazawa, R., and Ito, S. (2010). A novel bioactive haemodialysis system using dissolved dihydrogen (H2) produced by water electrolysis: A clinical trial. Nephrol. Dial. Transpl. 25, 3026–3033. doi:10.1093/ndt/gfq196
Nieto, F. J., Young, T. B., Lind, B. K., Shahar, E., Samet, J. M., Redline, S., et al. (2000). Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. J. Am. Med. Assoc. 283, 1829–1836. doi:10.1001/jama.283.14.1829
Ohsawa, I., Ishikawa, M., Takahashi, K., Watanabe, M., Nishimaki, K., Yamagata, K., et al. (2007). Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat. Med. 13, 688–694. doi:10.1038/nm1577
Si, Y., Tian, H., Dong, B., Zhang, Y., Wen, Y., Jia, X., et al. (2021). Effects of hydrogen as adjuvant treatment for unstable angina. Exp. Biol. Med. 246, 1981–1989. doi:10.1177/15353702211009138
Sugai, K., Tamura, T., Sano, M., Uemura, S., Fujisawa, M., Katsumata, Y., et al. (2020). Daily inhalation of hydrogen gas has a blood pressure-lowering effect in a rat model of hypertension. Sci. Rep. 10, 20173. doi:10.1038/s41598-020-77349-8
Tanaka, Y., Saihara, Y., Izumotani, K., and Nakamura, H. (2018). Daily ingestion of alkaline electrolyzed water containing hydrogen influences human health, including gastrointestinal symptoms. Med. Gas. Res. 8, 160–166. doi:10.4103/2045-9912.248267
Tao, G., Zhang, G., Chen, W., Yang, C., Xue, Y., Song, G., et al. (2022). A randomized, placebo‐controlled clinical trial of hydrogen/oxygen inhalation for non‐alcoholic fatty liver disease. J. Cell. Mol. Med. 26, 4113–4123. doi:10.1111/jcmm.17456
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., et al. (2020). Heart disease and stroke statistics—2020 update: A report from the American heart association. Circulation 141, e139–e596. doi:10.1161/CIR.0000000000000757
Wang, Y., Jing, L., Zhao, X.-M., Han, J.-J., Xia, Z.-L., Qin, S.-C., et al. (2011). Protective effects of hydrogen-rich saline on monocrotaline-induced pulmonary hypertension in a rat model. Respir. Res. 12, 26–28. doi:10.1186/1465-9921-12-26
Wang, Z., Chen, Z., Zhang, L., Wang, X., Hao, G., Zhang, Z., et al. (2018). Status of hypertension in China: Results from the China hypertension survey, 2012–2015. Circulation 137, 2344–2356. doi:10.1161/CIRCULATIONAHA.117.032380
Whitworth, J. A., Mangos, G. J., and Kelly, J. J. (2000). Cushing, cortisol, and cardiovascular disease. Hypertension 36, 912–916. doi:10.1161/01.hyp.36.5.912
Wolf-Maier, K., Cooper, R. S., Banegas, J. R., Giampaoli, S., Hense, H.-W., Joffres, M., et al. (2003). Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. Jama 289, 2363–2369. doi:10.1001/jama.289.18.2363
Xin, H.-G., Zhang, B.-B., Wu, Z.-Q., Hang, X.-F., Xu, W.-S., Ni, W., et al. (2014). Consumption of hydrogen-rich water alleviates renal injury in spontaneous hypertensive rats. Mol. Cell. Biochem. 392, 117–124. doi:10.1007/s11010-014-2024-4
Yang, F., Chen, Z., Chen, S. A., Zhu, Q., Wang, L., Zhang, W., et al. (2019). Skin ulcers infected with conditional pathogenic strains treated with local hydrogen water packing in two pemphigus vulgaris patients: Case reports with follow‐up for 2 months. Dermatol. Ther. 32, e13027. doi:10.1111/dth.13027
Yu, Y.-S., and Zheng, H. (2012). Chronic hydrogen-rich saline treatment reduces oxidative stress and attenuates left ventricular hypertrophy in spontaneous hypertensive rats. Mol. Cell. Biochem. 365, 233–242. doi:10.1007/s11010-012-1264-4
Zanini, D., Todorovic, N., Korovljev, D., Stajer, V., Ostojic, J., Purac, J., et al. (2021). The effects of 6-month hydrogen-rich water intake on molecular and phenotypic biomarkers of aging in older adults aged 70 years and over: A randomized controlled pilot trial. Exp. Gerontol. 155, 111574. doi:10.1016/j.exger.2021.111574
Zhu, Q., Wu, Y., Li, Y., Chen, Z., Wang, L., Xiong, H., et al. (2018). Positive effects of hydrogen-water bathing in patients of psoriasis and parapsoriasis en plaques. Sci. Rep. 8, 8051–8058. doi:10.1038/s41598-018-26388-3